# Step 161 - Governed Expansion Scope Review

**Step 161 is a governed expansion-scope review only. It does not authorize or implement Step 162.**

Step 160 was verified as PASS, including baseline admissibility, tamper detection, fail-closed No-Bind behavior, recovery, display-only RAMAT output, audit evidence, reconstruction, and SHA-256 file integrity.

## Locked doctrine

- Platform B v1 remains ARCHITECTURE LOCKED.
- Thread D v1 remains ARCHITECTURE LOCKED.
- New advanced evaluation logic belongs only to Platform B1 / MVP2.
- Thread D2 and RAMAT Vision remain DISPLAY / WITNESS ONLY.
- Qualified humans and authorized organizational roles retain binding authority.
- Official records and execution remain in governed source systems.
- IRLT, compounding pharmacy, and DSCSA remain equal first-tier tracks.
- No production, PHI, physical regulated execution, or real wearable integration is authorized.

## First-tier expansion tracks

| Track | Priority | Proposed next slice | Selection state |
|---|---|---|---|
| TIER1-COMPOUNDING - Compounding Pharmacy Assurance Track | FIRST-TIER | Patient-Specific Order, Formula, Ingredient, Preparation, Label, Pharmacist Authority, and Dispensing Readiness Slice | HUMAN GOVERNED SELECTION REQUIRED |
| TIER1-DSCSA - DSCSA and Pharmaceutical Supply-Chain Assurance Track | FIRST-TIER | Serialization, EPCIS, Trading-Partner Authority, Transaction Evidence, Suspect-Product Hold, and Custody Transfer Readiness Slice | HUMAN GOVERNED SELECTION REQUIRED |
| TIER1-IRLT - IRLT and Radiopharmaceutical Assurance Track | FIRST-TIER | Time-Critical IRLT Manufacturing, QC Release, Custody, Decay-Window, and Administration Readiness Slice | HUMAN GOVERNED SELECTION REQUIRED |

## Track details

### TIER1-COMPOUNDING - Compounding Pharmacy Assurance Track

- Strategic position: Equal first-tier commercialization and demonstration priority
- Proposed next slice: Patient-Specific Order, Formula, Ingredient, Preparation, Label, Pharmacist Authority, and Dispensing Readiness Slice
- Step 160 reuse: Regulated-object identity; evidence integrity; rehashing; dependency checks; human authority; No-Bind; admissibility; RAMAT display contract; reconstruction
- New assurance focus: Mock patient-order binding; formulation identity; ingredient and lot genealogy; calculation verification; equipment and environmental readiness; beyond-use timing; pharmacist accountability; label agreement
- Synthetic scenario: Fictional patient-specific preparation is evaluated from mock prescription and formula through ingredient selection, compounding, verification, labeling, pharmacist review, and dispensing readiness.
- Required human authority: Authorized prescriber context; qualified compounding personnel; authorized pharmacist; accountable pharmacy management role
- Governed source systems: Mock pharmacy system; mock formulation record; mock inventory; mock equipment record; mock environmental record; mock dispensing record
- RAMAT Vision role: DISPLAY / WITNESS ONLY for order identity, ingredients, calculation, timing, label state, pharmacist authority, No-Bind, and readiness prompts
- Explicit exclusions: No real patient; no PHI; no actual prescription; no real drug preparation; no dispensing; no administration; no production pharmacy integration
- Implementation status: **CANDIDATE SCOPE ONLY - NOT IMPLEMENTED**

### TIER1-DSCSA - DSCSA and Pharmaceutical Supply-Chain Assurance Track

- Strategic position: Equal first-tier commercialization and demonstration priority
- Proposed next slice: Serialization, EPCIS, Trading-Partner Authority, Transaction Evidence, Suspect-Product Hold, and Custody Transfer Readiness Slice
- Step 160 reuse: Canonical object identity; evidence hashing and rehashing; source agreement; authority evaluation; No-Bind; action admissibility; display-only contract; reconstruction
- New assurance focus: Product identifier; serial; lot; expiration; aggregation; EPCIS event sequence; trading-partner authority; transaction evidence; suspect and illegitimate product state; saleable-return verification
- Synthetic scenario: Fictional serialized AURORA-17 product is evaluated across manufacturer, wholesaler, dispenser, transaction evidence, custody events, and suspect-product handling.
- Required human authority: Authorized manufacturer, trading-partner, compliance, investigation, and disposition roles
- Governed source systems: Mock serialization repository; mock EPCIS service; mock ERP; mock warehouse system; mock trading-partner registry; mock investigation record
- RAMAT Vision role: DISPLAY / WITNESS ONLY for serialization identity, EPCIS agreement, partner authority, suspect-product state, No-Bind, and transfer readiness
- Explicit exclusions: No real serialized product; no production EPCIS exchange; no live trading partner; no shipment execution; no product quarantine or disposition
- Implementation status: **CANDIDATE SCOPE ONLY - NOT IMPLEMENTED**

### TIER1-IRLT - IRLT and Radiopharmaceutical Assurance Track

- Strategic position: Equal first-tier commercialization and demonstration priority
- Proposed next slice: Time-Critical IRLT Manufacturing, QC Release, Custody, Decay-Window, and Administration Readiness Slice
- Step 160 reuse: Regulated-object identity; SHA-256 evidence sealing; rehashing; QC dependency evaluation; human release authority; No-Bind; admissibility; display contract; reconstruction; backup and recovery
- New assurance focus: Radionuclide identity; decay timing; material genealogy; equipment state; environmental conditions; chain of custody; carrier and receiving authority; patient-specific administration window
- Synthetic scenario: Fictional AURORA-17 radiopharmaceutical batch moves from manufacturing through QC release, custody transfer, transport, receipt, and administration readiness.
- Required human authority: Qualified manufacturing personnel; Quality Unit or authorized batch releaser; authorized logistics or custody roles; authorized clinical personnel
- Governed source systems: Mock MES; mock LIMS; mock eQMS; mock ERP; mock custody record; mock clinical or administration system
- RAMAT Vision role: DISPLAY / WITNESS ONLY for timing, identity, integrity, custody, No-Bind, admissibility, and human-action prompts
- Explicit exclusions: No real radionuclide; no patient; no PHI; no production MES or LIMS; no physical release; no transport execution; no clinical administration
- Implementation status: **CANDIDATE SCOPE ONLY - NOT IMPLEMENTED**

## Governance gates

| Gate | Requirement | Status |
|---|---|---|
| GATE-161-01 - Explicit Human Scope Authorization | An accountable human must explicitly authorize the exact Step 162 scope. | REQUIRED |
| GATE-161-02 - Platform B v1 Architecture Lock | Platform B v1 remains limited to its six frozen MVP capabilities. | LOCKED |
| GATE-161-03 - Thread D v1 Architecture Lock | Thread D v1 remains unchanged and continues to display only Platform B v1 state. | LOCKED |
| GATE-161-04 - Platform B1 Evaluation Boundary | New advanced evaluation logic belongs only to Platform B1 / MVP2. | REQUIRED |
| GATE-161-05 - RAMAT Display-Only Boundary | Thread D2 and RAMAT Vision remain DISPLAY / WITNESS ONLY. | REQUIRED |
| GATE-161-06 - Human Authority Boundary | Qualified humans and authorized organizational roles retain binding authority. | REQUIRED |
| GATE-161-07 - Official Source-System Boundary | Official records and execution remain in governed source systems. | REQUIRED |
| GATE-161-08 - Synthetic Data Boundary | Step 162 must use mock identities and synthetic non-production data only. | REQUIRED |
| GATE-161-09 - Fail-Closed No-Bind Requirement | Missing or conflicted identity, integrity, dependency, authority, timing, or security state must produce or preserve a hold. | REQUIRED |
| GATE-161-10 - Hashing and Rehashing Requirement | The next slice must preserve evidence sealing, rehash verification, tamper detection, and chain-of-custody truth. | REQUIRED |
| GATE-161-11 - Security and Recovery Evidence | The next slice must include tests, audit evidence, reconstruction, integrity manifest, backup or reset path, and explicit recovery behavior. | REQUIRED |
| GATE-161-12 - No Production or Physical Execution | No production integration, physical manufacturing, dispensing, shipment, clinical administration, or regulated execution is authorized. | REQUIRED |

## Proposed Step 162 shared scope

- Proposed title: First-Tier Triad Shared Assurance Expansion Authorization
- Purpose: Authorize one governed local non-production implementation expansion or a shared reusable kernel increment supporting IRLT, compounding pharmacy, and DSCSA without demoting any first-tier track.
- Authorization state: **NOT AUTHORIZED**
- Authorization reason: Explicit accountable human authorization is required after review of Step 161.

### Permitted shared capabilities after authorization

- Reusable regulated-object identity extension
- Reusable evidence integrity and rehash workflow
- Reusable workflow dependency evaluator
- Reusable authority and delegation evaluator
- Reusable temporal-validity evaluator
- Reusable No-Bind state evaluator
- Reusable action-admissibility record
- Reusable display-only RAMAT contract
- Reusable reconstruction and audit package
- Reusable synthetic scenario-fixture format

### Prohibited actions

- Modify Platform B v1
- Modify Thread D v1
- Connect production source systems
- Use PHI or company production data
- Approve or execute regulated actions
- Release product
- Dispense or administer medication
- Transfer real serialized product
- Integrate physical wearable hardware
- Claim regulatory or production validation

## Step 162 authorization gate

Step 162 must not begin until an accountable human explicitly authorizes the next scope after reviewing the three equal first-tier tracks, the shared-kernel option, governance gates, exclusions, security boundaries, human-authority requirements, and source-system boundaries.

**STEP 161 GOVERNED EXPANSION SCOPE REVIEW COMPLETE**

**STEP 162: AWAITING EXPLICIT HUMAN AUTHORIZATION**

